Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ibio Inc (IBIO)

Ibio Inc (IBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 265,878
  • Shares Outstanding, K 182,108
  • Annual Sales, $ 1,640 K
  • Annual Income, $ -16,440 K
  • 60-Month Beta -5.92
  • Price/Sales 163.43
  • Price/Cash Flow N/A
  • Price/Book 3.29
Trade IBIO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/13
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4000 +7.86%
on 11/27/20
2.1100 -28.44%
on 11/16/20
-0.4100 (-21.35%)
since 10/27/20
3-Month
1.4000 +7.86%
on 11/27/20
2.6200 -42.37%
on 09/17/20
-0.6000 (-28.44%)
since 08/27/20
52-Week
0.1090 +1,285.32%
on 11/29/19
7.4500 -79.73%
on 07/21/20
+1.4010 (+1,285.32%)
since 11/27/19

Most Recent Stories

More News
Diagnostic Capabilities Remain of Utmost Importance as Cases Surge Worldwide

, /PRNewswire/ -- As of earlier this week, the U.S. has reported more than 12.4 million cases and over 257,600 deaths, . Dr. , the National Institute of Allergy and Infectious Diseases, has also...

CYDY : 2.6600 (-0.37%)
AYTU : 0.9198 (+2.20%)
NVAX : 125.69 (+22.50%)
IBIO : 1.5100 (+3.42%)
iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis

iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced that the United States Patent and Trademark Office has issued U.S....

FSNN : 0.0580 (-19.44%)
IBIO : 1.5100 (+3.42%)
iBio Reports Fiscal First Quarter 2021 Financial Results and Provides Corporate Update

iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal quarter ended September 30,...

IBIO : 1.5100 (+3.42%)
New Surge of Cases Emphasizes the Need for Widespread Diagnostic Solutions

, /PRNewswire/ -- New restrictions are being implemented in several states across the country as the number of those infected with COVID-19 is once again on the rise. For instance, new restrictions went...

DVAX : 4.79 (+12.71%)
TOMDF : 0.0550 (-4.35%)
HTBX : 1.1400 (+3.64%)
VXRT : 7.03 (+9.84%)
IBIO : 1.5100 (+3.42%)
iBio to Participate in Alliance Global Partners' Virtual Healthcare Symposium

iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced that management will participate in Alliance Global Partners' Virtual...

IBIO : 1.5100 (+3.42%)
iBio to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Update on Monday, November 16 ,2020

iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 first quarter financial results...

IBIO : 1.5100 (+3.42%)
iBio Announces Appointment of Randy J. Maddux as Chief Operating Officer

iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Randy J. Maddux as its Chief Operating Officer...

IBIO : 1.5100 (+3.42%)
5 "Strong Sell" Stocks on the Robinhood 100 to Avoid

The Robinhood 100 has become known as a barometer of millennial investing trends due to its focus on the top 100 stocks owned by users of the Robinhood trading platform. But many of the stock on the list...

CCL : 21.58 (+4.50%)
INO : 12.26 (+18.00%)
SRNE : 8.15 (+18.12%)
IBIO : 1.5100 (+3.42%)
AMC : 4.45 (-0.89%)
Recent Events Reinforce the Importance of Surface Sterilization

, /PRNewswire/ -- The pandemic continues to take a toll on the world's economy, and as a result, effective and cheap mass testing is needed to properly implement preventive measures. Since the pandemic...

ABT : 107.62 (+1.14%)
VYST : 0.0373 (-5.57%)
RLFTF : 0.4435 (+4.11%)
IBIO : 1.5100 (+3.42%)
OGEN : 0.4149 (+5.28%)
PCTL : 0.0206 (-4.19%)
iBio Announces Appointment of Dr. Alexandra Kropotova to Board of Directors

- Senior Biopharm Executive with 20 Years of Immuno-Inflammatory Disease Therapeutic Experience -

IBIO : 1.5100 (+3.42%)
TEVA : 9.82 (+0.72%)
SAN : 2.91 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture...

See More

Key Turning Points

2nd Resistance Point 1.6100
1st Resistance Point 1.5600
Last Price 1.5100
1st Support Level 1.4300
2nd Support Level 1.3500

See More

52-Week High 7.4500
Fibonacci 61.8% 4.6457
Fibonacci 50% 3.7795
Fibonacci 38.2% 2.9133
Last Price 1.5100
52-Week Low 0.1090

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar